KRAS and neoplasm: Recently, preclinical studies on TSN1611, a potential KRAS G12D(ON/OFF) inhibitor developed by Tyligand Bioscience, showed its favorable safety profiles and significant in vitro and in vivo anti-tumor activity in various KRAS G12D-mutant models, as well as its brain penetration potential [90].